Published in Medical Device Business Week, February 8th, 2006
The antitrust clearances in Germany and Spain are the only antitrust approvals required outside of the United States.
Allergan and Inamed are continuing to work with the Federal Trade Commission staff to complete Inamed's divestiture of its license to Reloxin. Such divestiture is being discussed to facilitate the antitrust approval of Allergan's acquisition of Inamed in the United States, which is the only remaining antitrust clearance required to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.